NCT02530008View on ClinicalTrials.gov

Breast Cancer 2-PREVENT Translational Center of Excellence (TCE) - Metastatic Markers of Recurrent Tumor Phenotype for Breast Cancer

Active, not recruitingOBSERVATIONAL
Enrollment

600

Participants

Timeline

Start Date

October 31, 2013

Primary Completion Date

October 31, 2024

Study Completion Date

October 31, 2026

Conditions
Women With Suspected or Confirmed Recurrent Breast Cancer
Trial Locations (2)

17602

Lancaster General Hospital, Lancaster

19104

Abramson Cancer Center of the University of Pennsylvania, Philadelphia

All Listed Sponsors
lead

Abramson Cancer Center at Penn Medicine

OTHER